Navigation Links
Yondelis(R) Receives Five New Approvals Outside the European Economic Area

MADRID, March 15 /PRNewswire/ -- Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Israel, Panama and Ukraine have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults. Furthermore, the authorities in Paraguay and Azerbaijan have approved the drug for platinum-sensitive recurrent ovarian cancer (ROC). Yondelis is already approved for STS in Paraguay and Azerbaijan.

The European Commission approved Yondelis(R) for platinum-sensitive ROC in September 2009. Outside the European Economic Area (EEA), Yondelis(R) has now been approved for platinum-sensitive ROC in Azerbaijan and Paraguay; it had already been approved in Kazakhstan and the Philippines.

In view of the three new approvals for STS, Yondelis(R) now has authorization for this indication in 25 countries outside the EEA: Argentina, Azerbaijan, Bolivia, Chile, Colombia, Curacao, Hong Kong, India, Israel, Kazakhstan, Macao, Malaysia, Mexico, Panama, Paraguay, The Philippines, Russia, Singapore, South Korea, Switzerland, Thailand, Ukraine, Uruguay, Venezuela and Vietnam. PharmaMar has already begun collecting royalties from sales in the aforementioned countries.

Clinical trials are under way to expand the use of Yondelis(R) in sarcoma, including a trial as first-line treatment in patients with translocation-associated tumors, in children with Ewing sarcoma, rhabdomyosarcoma and other forms of STS. Yondelis(R) is also undergoing trials in solid tumors, such as prostate, breast and lung cancer.

Yondelis(R) has orphan drug status for soft tissue sarcoma and ovarian cancer in the European Union, the United States, Switzerland, and for soft tissue sarcoma in South Korea.

According to the licensing agreement between PharmaMar (Zeltia, S.A. subsidiary) and Centocor Ortho Biotech Products, L.P., PharmaMar has the rights to sell Yondelis(R) in Europe (including Eastern Europe), while Centocor Ortho Biotech Products, L.P. has the rights to sell the drug everywhere else, except in Japan, where Taiho Pharmaceutical Co., Ltd. has a licensing agreement for the development and sale of Yondelis(R).

About PharmaMar

PharmaMar is Zeltia Group's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis(R) is Spain's first anti-cancer drug. It is currently approved for STS in 25 countries outside the EEA, and in five of those countries for platinum-sensitive ROC as well. Yondelis(R) is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Phase II clinical trials with Yondelis(R) are also under way on prostate, breast, lung and pediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin(R), Irvalec(R), Zalypsis(R) and PM01183. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programs.

Important note

PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of the Zeltia Group (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

SOURCE Group Zeltia

Back to top
SOURCE Group Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... Vereb has been named the organization’s Executive Vice President of Operations, and three ... to key leadership roles in the company. , Debbie Vereb’s appointment to Executive ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and animal health products, ... Technology, and will lead a new, dedicated global team of drug development and ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... According to an article published ... from adults today versus those of a similar group taken in 1988 has shown that ... a person in 2008 with the same diet as someone in 1971 would be on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The American Society of Clinical ... professional education and clinical training in a health care discipline. , Many ... such as: losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, creators of the ... honor of Breast Cancer Awareness Month. During the month of October, for ... SleepPhones® Classic product to a breast cancer patient at the Cleveland Clinic. , ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Oct. 12, 2015  Millions of smokers worldwide have ... shackles of tobacco. An April 2015 study ... London showed electronic cigarettes to be up to 95 ... than a decade after the technology was first introduced ... --> --> ...
(Date:10/12/2015)... , Oct. 12, 2015 About epilepsy ... to a spectrum of brain disorders manifested by benign ... by factors ranging from brain malformations and tumors to ... underlying cause of the disease is unidentified, as is ... as idiopathic epilepsy. An imbalance between the inhibitory and ...
(Date:10/12/2015)... , October 12, 2015 --> ... report "Spirometer Market by Product (Hand-held, Table-top, Desktop), Technology (Volume ... Application, & Geography - Global Forecast to 2020", published by ... Million by 2020, at a CAGR of 9.8% from 2015 ... 128 F igures spread th rough 187 P ...
Breaking Medicine Technology: